EU/3/20/2283: Orphan designation for the treatment of neonatal encephalopathy
Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24
Table of contents
Overview
On 4 June 2020, orphan designation EU/3/20/2283 was granted by the European Commission to Clinipace GmbH, Germany, for Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy.
Key facts
Active substance |
Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24
|
Intended use |
Treatment of neonatal encephalopathy
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/20/2283
|
Date of designation |
04/06/2020
|
Sponsor |
Clinipace GmbH |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: